查看购物车
  • Traditional Chinese
  • English
  • Japanese
欧洲生物製剂药物研发市场：按製造商、类型和国家分類的分析和预测（2025-2035 年）
市场调查报告书
商品编码
1892734

欧洲生物製剂药物研发市场：按製造商、类型和国家分類的分析和预测（2025-2035 年）

Europe Biologics Drug Discovery Market: Focus on Manufacturing Type, Type, and Country - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 81 Pages | 商品交期: 1-5个工作天内

价格

欧洲生物製剂药物研发市场预计将从 2024 年的 64.3 亿美元成长到 2035 年的 171.6 亿美元，在预测期（2025-2035 年）内以 9.36% 的复合年增长率增长。

市场成长主要受罕见疾病和慢性病患者增多以及对精准标靶治疗需求不断增长的推动。生物製剂，包括单株抗体、重组蛋白以及新一代治疗方法的研发，因其优于传统小分子疗法的疗效、安全性和选择性，在全部区域日益普及。神经病学、免疫学和肿瘤学等关键治疗领域的进展，得益于欧洲强大的创新生态系统，以及政府资助的研究计画、产学合作和不断完善的监管指南的支持。

关键市场统计数据
预测期 2025-2035
2025 年评估 70.1亿美元
2035 年预测 171.6亿美元
复合年增长率 9.36%

技术进步正进一步提升该地区的药物研发能力。高通量筛检、多组体学整合、人工智慧辅助标靶选择以及先进的抗体设计平台，在提高早期研发效率的同时，也增加了临床成功的几率。然而，该产业仍面临许多结构性挑战，包括研发成本高昂、生物製剂生产流程复杂以及欧洲各国在研发能力和熟练劳动力方面的差距。但随着投资的增加、外包给专业合约研究组织（CRO）和合约研发生产机构（CDMO）的趋势日益明显，以及个人化医疗的兴起，欧洲已做好充分准备，在引领生物製剂发展方向和下一代治疗创新方面发挥关键作用。

市场概览

在快速的科学进步、不断变化的治疗需求以及全部区域强劲的投资活动的推动下，欧洲生物製剂药物研发市场正经历变革时期。随着生物製剂不断展现出超越传统小分子药物的临床成功和商业性价值，欧洲已成为先进药物研发平台、抗体工程、细胞和基因治疗研究以及RNA疗法和多特异性抗体等新一代疗法的关键中心。

人口老化、慢性病盛行率上升以及对个人化和标靶治疗日益增长的需求，使得高价值生物製剂在该地区的重要性更加凸显。製药公司、生技新兴企业、合约研究组织 (CRO) 和合约研发开发机构 (CDMO) 之间的合作正在不断扩大，以加速药物发现、优化先导化合物并儘早识别出有效成分。早期研究正因数位技术的变革而转变，尤其是人工智慧驱动的蛋白质设计、In Silico模拟和数据驱动的生物标记识别。

同时，欧洲监管环境的变化，特别是新的欧盟卫生技术评估（HTA）框架，正迫使研发人员在研发早期阶段就提供更多比较性证据和真实世界证据（RWE）。虽然这增加了研发的复杂性，但也有助于确保高品质的创新，并加速创新治疗方法的应用。总体而言，欧洲正透过将卓越的科学实力与不断扩大的研发和商业化合作伙伴网络相结合，巩固其在生物製剂发现领域的全球领先地位。

市场区隔:

细分 1：依生产类型

  • 内部生产
  • 外包委託製造

细分 2：按类型

  • 单株抗体
  • 重组蛋白
  • 其他生物製剂

细分3：按地区

  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的

本报告调查了欧洲生物製剂药物发现市场，并总结了关键趋势、市场影响因素分析、法律制度、市场规模趋势和预测、按各个细分市场、地区/主要国家进行的详细分析、竞争格局以及主要企业的概况。

目录

执行摘要

范围和定义

第一章 欧洲生物製剂药物研发市场：产业展望

  • 市场概览
  • 主要市场趋势
    • 双特异性和多特异性抗体研发进展
    • 加强伙伴关係与合作
    • 对外包服务的需求不断增长
  • 监管状态
    • 欧洲
  • 供应链分析
    • 供应炼及其风险
  • 市场动态
    • 市场驱动因素
    • 市场挑战
    • 市场机会

第二章：生物製剂药物研发市场（依地区分）

  • 欧洲
    • 区域概览
    • 市场成长驱动因素
    • 市场问题
    • 市场规模及预测

第三章 竞争基准化分析与公司概况

  • 各公司的主要策略和发展
  • 公司简介
    • AstraZeneca Plc
    • Evotec SE
    • F. Hoffmann-La Roche AG
    • Merck KGaA
    • Novo Nordisk A/S
    • Novartis AG

第四章调查方法

Product Code: BHP3491SS

This report can be delivered in 2 working days.

Introduction to Europe Biologics Drug Discovery Market

The Europe biologics drug discovery market is projected to reach $17.16 billion by 2035 from $6.43 billion in 2024, growing at a CAGR of 9.36% during the forecast period 2025-2035. The increasing prevalence of uncommon and chronic diseases as well as the growing need for precision-targeted treatments are driving the biologics drug discovery industry in Europe. Due to their superior therapeutic effects, greater safety profiles, and increased selectivity as compared to traditional small-molecule treatments, biologics-which include monoclonal antibodies, recombinant proteins, and developing next-generation modalities-are becoming more and more popular throughout the region. Developments in important therapeutic fields like neurology, immunology, and oncology are being accelerated by Europe's robust innovation ecosystem, which is supported by government-funded research programs, academic-industry collaborations, and changing regulatory guidelines.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$7.01 Billion
2035 Forecast$17.16 Billion
CAGR9.36%

Technological developments are improving the area's capacity for discovery even more. High-throughput screening, multi-omics integration, AI-enabled target selection, and advanced antibody-engineering platforms are raising the likelihood of clinical success and enhancing early-stage efficiency. High R&D expenses, complicated biologics manufacturing, and differences in research capacity and skilled labor among European nations are some of the structural issues that the sector still faces. Nevertheless, Europe is positioned to play a major role in determining the direction of biologics drug development and next-generation therapeutic innovation due to growing investments, increased outsourcing to specialized CROs and CDMOs, and a growing shift toward personalized medicine.

Market Introduction

The Europe biologics drug discovery market is undergoing a transitional period, propelled by swift scientific advancements, changing therapeutic requirements, and robust investment activity throughout the area. Europe has become a vital center for advanced discovery platforms, antibody engineering, cell and gene therapy research, and next-generation modalities like RNA therapeutics and multispecific antibodies as biologics continue to surpass conventional small-molecule drugs in clinical success and commercial value.

The region's emphasis on high-value biologics is being strengthened by aging populations, an increase in the prevalence of chronic diseases, and a growing need for tailored, targeted treatments. Collaborations between pharmaceutical corporations, biotech startups, CROs, and CDMOs are growing in order to expedite translational development, optimize lead candidates, and speed up hit identification. Early-stage research is being transformed by digital technologies, particularly AI-driven protein design, in silico modeling, and data-driven biomarker identification.

At the same time, Europe's changing regulatory landscape, especially the new EU HTA framework, is requiring developers to create more comparative and real-world evidence earlier in the pipeline. Although this makes things more complicated, it also guarantees excellent innovation and quicker adoption of ground-breaking treatments. All things considered, Europe is establishing itself as a world leader in biologics discovery by fusing scientific brilliance with an expanding network of research and commercialization partners.

Market Segmentation:

Segmentation 1: By Manufacturing Type

  • In-House Manufacturing
  • Outsourced Manufacturing

Segmentation 2: By Type

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Other Biologics

Segmentation 3: By Region

  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe

Europe Biologics Drug Discovery Market Trends, Drivers and Challenges

Market Trends

  • Strong expansion of biologics as one of Europe's fastest-growing pharmaceutical segments.
  • Shift toward advanced modalities such as cell and gene therapies, RNA therapeutics, multispecifics, and ADCs.
  • Rising integration of AI, machine learning, and computational protein design to accelerate early-stage discovery.
  • Increased partnerships, licensing deals, and outsourcing to CROs/CDMOs for specialized discovery capabilities.
  • Growing biosimilar development influencing portfolio decisions and lifecycle management.

Market Growth Drivers

  • Advancements in high-throughput screening, single-cell analysis, and structural biology speeding up target validation.
  • Ageing population and rising prevalence of chronic and rare diseases boosting demand for innovative biologics.
  • Strong investment inflow from pharma, biotech, VC, and strategic collaborations supporting R&D.
  • Supportive innovation initiatives and evolving regulatory frameworks encouraging advanced biologics.
  • Increasing use of real-world data and digital platforms for biomarker research and target selection.

Market Challenges

  • Complex and fragmented regulatory and HTA pathways across Europe affecting approval and access timelines.
  • Intensifying pricing pressure and reimbursement hurdles due to payer scrutiny and biosimilar competition.
  • High manufacturing and CMC complexity leading to elevated development costs and longer timelines.
  • Talent shortage in specialized areas like protein engineering, biologics CMC, and regulatory sciences.
  • Supply-chain vulnerabilities linked to dependence on external regions for APIs and CDMO capacity.

How can this report add value to an organization?

Product/Innovation Strategy: The Europe biologics drug discovery market has been extensively segmented based on various categories, such as manufacturing type, type, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Partnerships, alliances, and business expansions have accounted for the majority of key developments.

Competitive Strategy: The Europe biologics drug discovery market has numerous established players with product portfolios. Key players in the Europe biologics drug discovery market, analyzed and profiled in the study, include established players offering platforms, products, and services for biologics drug discovery.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • AstraZeneca Plc
  • Evotec SE
  • Merck KGaA
  • Novo Nordisk A/S
  • Novartis AG
  • F. Hoffmann-La Roche AG

Table of Contents

Executive Summary

Scope and Definition

1 Europe Biologics Drug Discovery Market: Industry Outlook

  • 1.1 Market Overview
  • 1.2 Key Market Trends
    • 1.2.1 Growth of Bispecific and Multispecific Antibody Development
    • 1.2.2 Rising Partnerships and Collaborations
    • 1.2.3 Rising Demand for Outsourcing Services
  • 1.3 Regulatory Landscape
    • 1.3.1 Europe
      • 1.3.1.1 Germany
      • 1.3.1.2 France
      • 1.3.1.3 Italy
  • 1.4 Supply Chain Analysis
    • 1.4.1 Supply Chain and Risks within the Supply Chain
  • 1.5 Market Dynamics
    • 1.5.1 Market Drivers
      • 1.5.1.1 Rising Prevalence of Chronic and Rare Diseases Driving Demand for Biologics in Treatment
      • 1.5.1.2 Strong Investment and R&D Funding Leading to Increased Demand for Biologics
    • 1.5.2 Market Challenges
      • 1.5.2.1 High Development and Manufacturing Costs Hindering the Growth of the Market
    • 1.5.3 Market Opportunities
      • 1.5.3.1 AI Integration in Biologics Discovery

2 Biologics Drug Discovery Market (by Region), ($Billion), 2023-2035

  • 2.1 Europe
    • 2.1.1 Regional Overview
    • 2.1.2 Driving Factors for Market Growth
    • 2.1.3 Factors Challenging the Market
    • 2.1.4 Market Sizing and Forecast
      • 2.1.4.1 Europe Biologics Drug Discovery Market, by Manufacturing Type
      • 2.1.4.2 Europe Biologics Drug Discovery Market, by Type
      • 2.1.4.3 Europe Biologics Drug Discovery Market, by Country
        • 2.1.4.3.1 Germany
          • 2.1.4.3.1.1 Country Overview
          • 2.1.4.3.1.2 Driving Factors for Market Growth
          • 2.1.4.3.1.3 Factors Challenging the Market
          • 2.1.4.3.1.4 Market Sizing and Forecast
          • 2.1.4.3.1.4.1 Germany Biologics Drug Discovery Market, by Manufacturing Type
          • 2.1.4.3.1.4.2 Germany Biologics Drug Discovery Market, by Type
        • 2.1.4.3.2 U.K.
          • 2.1.4.3.2.1 Country Overview
          • 2.1.4.3.2.2 Driving Factors for Market Growth
          • 2.1.4.3.2.3 Factors Challenging the Market
          • 2.1.4.3.2.4 Market Sizing and Forecast
          • 2.1.4.3.2.4.1 U.K. Biologics Drug Discovery Market, by Manufacturing Type
          • 2.1.4.3.2.4.2 U.K. Biologics Drug Discovery Market, by Type
        • 2.1.4.3.3 France
          • 2.1.4.3.3.1 Country Overview
          • 2.1.4.3.3.2 Driving Factors for Market Growth
          • 2.1.4.3.3.3 Factors Challenging the Market
          • 2.1.4.3.3.4 Market Sizing and Forecast
          • 2.1.4.3.3.4.1 France Biologics Drug Discovery Market, by Manufacturing Type
          • 2.1.4.3.3.4.2 France Biologics Drug Discovery Market, by Type
        • 2.1.4.3.4 Italy
          • 2.1.4.3.4.1 Country Overview
          • 2.1.4.3.4.2 Driving Factors for Market Growth
          • 2.1.4.3.4.3 Factors Challenging the Market
          • 2.1.4.3.4.4 Market Sizing and Forecast
          • 2.1.4.3.4.4.1 Italy Biologics Drug Discovery Market, by Manufacturing Type
          • 2.1.4.3.4.4.2 Italy Biologics Drug Discovery Market, by Type
        • 2.1.4.3.5 Spain
          • 2.1.4.3.5.1 Country Overview
          • 2.1.4.3.5.2 Driving Factors for Market Growth
          • 2.1.4.3.5.3 Factors Challenging the Market
          • 2.1.4.3.5.4 Market Sizing and Forecast
          • 2.1.4.3.5.4.1 Spain Biologics Drug Discovery Market, by Manufacturing Type
          • 2.1.4.3.5.4.2 Spain Biologics Drug Discovery Market, by Type
        • 2.1.4.3.6 Rest-of-Europe
          • 2.1.4.3.6.1 Country Overview
          • 2.1.4.3.6.2 Driving Factors for Market Growth
          • 2.1.4.3.6.3 Factors Challenging the Market
          • 2.1.4.3.6.4 Market Sizing and Forecast
          • 2.1.4.3.6.4.1 Rest-of-Europe Biologics Drug Discovery Market, by Manufacturing Type
          • 2.1.4.3.6.4.2 Rest-of-Europe Biologics Drug Discovery Market, by Type

3 Competitive Benchmarking and Company Profiles

  • 3.1 Key Strategies and Developments by Company
    • 3.1.1 Funding Activities
    • 3.1.2 Mergers and Acquisitions
    • 3.1.3 Regulatory Approvals and Product Launches
    • 3.1.4 Partnerships, Collaborations, and Business Expansions
  • 3.2 Company Profiles
    • 3.2.1 AstraZeneca Plc
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products/Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers
      • 3.2.1.5 Key Personal
      • 3.2.1.6 Analyst View
    • 3.2.2 Evotec SE
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products/Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers
      • 3.2.2.5 Key Personal
      • 3.2.2.6 Analyst View
    • 3.2.3 F. Hoffmann-La Roche AG
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products/Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers
      • 3.2.3.5 Key Personal
      • 3.2.3.6 Analyst View
    • 3.2.4 Merck KGaA
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products/Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers
      • 3.2.4.5 Key Personal
      • 3.2.4.6 Analyst View
    • 3.2.5 Novo Nordisk A/S
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products/Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers
      • 3.2.5.5 Key Personal
      • 3.2.5.6 Analyst View
    • 3.2.6 Novartis AG
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products/Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers
      • 3.2.6.5 Key Personal
      • 3.2.6.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Europe Biologics Drug Discovery Market (by Scenario), $Billion, 2024, 2029, and 2035
  • Figure 2: Europe Biologics Drug Discovery Market, 2024 and 2035
  • Figure 3: Biologics Drug Discovery Market, $Billion, 2025 and 2035
  • Figure 4: Europe Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2025, 2029, and 2035
  • Figure 5: Europe Biologics Drug Discovery Market (by Type), $Billion, 2025, 2029, and 2035
  • Figure 6: Incidence of Cancer (by Region), 2020-2040
  • Figure 7: Europe Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 8: Germany Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 9: U.K. Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 10: France Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 11: Italy Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 12: Spain Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 13: Rest-of-Europe Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 14: Data Triangulation
  • Figure 15: Top-Down and Bottom-Up Approach
  • Figure 16: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Europe Biologics Drug Discovery Market, Key Market Trends
  • Table 3: Key Partnerships in the Biologics Drug Discovery Market
  • Table 4: Market Dynamics
  • Table 5: Biologics Drug Discovery Market (by Region), $Billion, 2023-2035
  • Table 6: Europe Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 7: Europe Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 8: Europe Biologics Drug Discovery Market (by Country), $Billion, 2023-2035
  • Table 9: Germany Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 10: Germany Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 11: U.K. Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 12: U.K. Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 13: France Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 14: France Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 15: Italy Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 16: Italy Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 17: Spain Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 18: Spain Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 19: Rest-of-Europe Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 20: Rest-of-Europe Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 21: Some of the Major Key Strategies: Funding Activities, January 2022 - September 2025
  • Table 22: Some of the Major Key Strategies: Mergers and Acquisitions, January 2022 - September 2025
  • Table 23: Some of the Major Key Strategies: Regulatory Approvals and Product Launches, January 2022 - September 2025
  • Table 24: Some of the Major Key Strategies: Partnerships, Collaborations, and Business Expansions, January 2022 - September 2025